Interview with Timothy C. Rodell, M.D., GlobeImmune CEO & President:
Can you describe the top priorities or upcoming milestones for your company?
Our phase 2 trial in chronic hepatitis C has completed enrollment and we expect to disclose end of treatment data at the annual meeting of the American Association for the Study of Liver Disease in October. We also expect to present the final data from this trial, sustained virologic response, early in 2010. We are continuing to mature our phase 2 trial in pancreas cancer and expect to provide data from that trial during 2010.
What is one aspect of your company that you feel would be most attractive or exciting to investors?
We will be disclosing a significant amount of clinical data over the next 12-18 months in two very important diseases. These data will also provide clinical proof-of-concept for our immunotherapy platform (Tarmogens). Additional targets for Tarmogen therapy include hepatitis B, non-small cell lung cancer (NSCLC) and colon cancer.
Based on your experience, what advice would you give to other execs in biotech today?
Novel therapies are expensive to develop and can take a long time to yield convincing results. Designing and running well-controlled clinical trials in the appropriate populations can be even more expensive, but in the long-run this provides the kind of quality data necessary to raise additional capital and find licensing partners.